Label at a glance#

ProductGamaSTAN

Active ingredientHuman Immunoglobulin G

Label structure15 sections

Boxed warning

Thrombosis may occur with immune globulin products, including GAMASTAN. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Warnings and Precautions (5.2) , Patien...

Indications and uses

GAMASTAN is a human immune globulin indicated for: GAMASTAN is indicated for prophylaxis following exposure to hepatitis A.( 1,2 ) The prophylactic value of GAMASTAN is greatest when given before or soon after exposure to hepatitis A. GAMASTAN is not indicated in persons with clinical manifestations of hepatitis A or in those exposed more than 2 weeks previously. GAMASTAN is indicated to prevent or modify measles ...

Dosage and administration

For intramuscular use only. Do not administer intravenously. Indication Dosage Instruction Prophylaxis for exposure to hepatitis A 0.1 mL/kg 0.05 milliliter per pound Administer within two weeks of prior exposure for household and institutional hepatitis A case contacts. Administer before departure to persons traveling to areas with endemic hepatitis A: 0.1 mL/kg if the length of stay will be up to 1 month( 9,10...

Storage and handling

GAMASTAN is supplied in 2 mL and 10 mL single dose vials. GAMASTAN contains no preservative and is not made with natural rubber latex. NDC Number Size 13533-335-04 2 mL vial 13533-335-12 10 mL vial Store GAMASTAN at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not use after expiration date.

Contacts and useful links#

PhoneLabel contact1-800-520-2807

PhoneFDA MedWatch1-800-FDA-1088

Websitewww.fda.gov

www.fda.gov/medwatch

Label contents#

Full prescribing information#

WARNING: THROMBOSIS

BOXED WARNING SECTION

Thrombosis may occur with immune globulin products, including GAMASTAN. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Warnings and Precautions (5.2), Patient Counseling Information (17)]
For patients at risk of thrombosis, do not exceed the recommended dose of GAMASTAN. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [ Warnings and Precautions (5.2) ]

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

GAMASTAN is a human immune globulin indicated for:

1.1 Hepatitis A

SPL UNCLASSIFIED SECTION

GAMASTAN is indicated for prophylaxis following exposure to hepatitis A.(1,2) The prophylactic value of GAMASTAN is greatest when given before or soon after exposure to hepatitis A. GAMASTAN is not indicated in persons with clinical manifestations of hepatitis A or in those exposed more than 2 weeks previously.

1.2 Measles (Rubeola)

SPL UNCLASSIFIED SECTION

GAMASTAN is indicated to prevent or modify measles in a susceptible person exposed fewer than 6 days previously.(3) A susceptible person is one who has not been vaccinated and has not had measles previously.

GAMASTAN may be especially indicated for susceptible household contacts of measles patients, particularly contacts under 1 year of age, for whom the risk of complications is highest.(3)
GAMASTAN is also indicated for pregnant women without evidence of immunity.
Do not give GAMASTAN and measles vaccine at the same time. If a child is older than 12 months and has received GAMASTAN, give measles vaccine about five months later when the measles antibody titer will have disappeared.(3,4) [see Drug Interactions (7) ] If a susceptible child exposed to measles is immunocompromised, give GAMASTAN immediately.

1.3 Varicella

SPL UNCLASSIFIED SECTION

GAMASTAN is indicated to modify varicella.

Passive immunization against varicella in immunosuppressed patients is best accomplished by use of Varicella Zoster Immune Globulin (Human). If unavailable, GAMASTAN, promptly given, may also modify varicella. (5,6)

1.4 Rubella

SPL UNCLASSIFIED SECTION

GAMASTAN is indicated to modify rubella in exposed women who will not consider a therapeutic abortion.

Some studies suggest that the use of GAMASTAN in exposed, susceptible women can lessen the likelihood of infection and fetal damage; therefore, GAMASTAN may benefit those women who will not consider a therapeutic abortion.(7)
Do not give GAMASTAN for routine prophylaxis of rubella in early pregnancy to an unexposed woman.(7)

1.5 Limitations of Use

SPL UNCLASSIFIED SECTION

GAMASTAN is not standardized with respect to antibody titers against hepatitis B surface antigen (HBsAg) and must not be used for prophylaxis of viral hepatitis type B. Prophylactic treatment to prevent hepatitis B can best be accomplished with use of Hepatitis B Immune Globulin (Human), often in combination with Hepatitis B Vaccine.(8)
GAMASTAN is not indicated for routine prophylaxis or treatment of rubella, poliomyelitis, mumps, or varicella.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For intramuscular use only.

Do not administer intravenously.

2.1 Dose

SPL UNCLASSIFIED SECTION

Indication	Dosage	Instruction
Prophylaxis for exposure to hepatitis A	0.1 mL/kg^*	Administer within two weeks of prior exposure for household and institutional hepatitis A case contacts.
		Administer before departure to persons traveling to areas with endemic hepatitis A:
	0.1 mL/kg	if the length of stay will be up to 1 month(9,10)
	0.2 mL/kg	if the length of stay will be up to 2 months(9,10)
	0.2 mL/kg	if the length of stay will be 2 months or longer; repeat every 2 months.(9,10)
Prevent or modify measles in a susceptible person exposed fewer than six days previously	0.25 mL/kg^†	Administer to a susceptible person within 6 days of exposure.
	0.5 mL/kg	Immediately administer (maximum dose, 15 mL) to an immunocompromised child.
Modify varicella	0.6 mL/ kg to 1.2 mL/kg	Administer promptly only if Varicella-Zoster Immune Globulin (Human) is unavailable.
Modify rubella only in an exposed woman who will not consider a therapeutic abortion	0.55 mL/kg	Only administer to an exposed pregnant woman who will not consider a therapeutic abortion.

* 0.05 milliliter per pound

† 0.11 milliliter per pound

2.2 Preparation and Handling

SPL UNCLASSIFIED SECTION

If the product shows any sign of tampering, do not use it and notify Grifols Therapeutics LLC immediately [1-800-520-2807].
Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. GAMASTAN is a clear or slightly opalescent, and colorless to pale yellow sterile solution.

2.3 Administration

SPL UNCLASSIFIED SECTION

Administer GAMASTAN intramuscularly, preferably in the anterolateral aspects of the upper thigh and the deltoid muscle of the upper arm. Do not use the gluteal region as an injection site because of the risk of injury to the sciatic nerve.(4) [see Warnings and Precautions (5.3)]
Draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel. [see Warnings and Precautions (5.3)]
Divide and inject doses greater than 10 mL into several muscle sites to reduce local pain and discomfort. An individual decision as to which muscle is injected must be made for each patient based on the volume of material to be administered.
If Hepatitis A Vaccine is recommended along with GAMASTAN, administer simultaneously but at separate anatomical sites.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

GAMASTAN is a sterile, 16.5% protein solution supplied in 2 mL and 10 mL single-dose vials.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

GAMASTAN is contraindicated in:

Anaphylactic or severe systemic hypersensitivity reactions to Immune Globulin (Human).(11) [see Warnings and Precautions (5.1)]
IgA deficient patients with antibodies against IgA and a history of hypersensitivity.(11)

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Administer GAMASTAN cautiously to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.(11) Have epinephrine available for treatment of acute allergic symptoms, should they occur.

Do not perform skin tests. In most patients the intradermal injection of concentrated gamma globulin solution with its buffers causes a localized area of inflammation which can be misinterpreted as a positive allergic reaction. In actuality, this does not represent an allergy; rather, it is localized tissue irritation of a chemical nature. Misinterpretation of the results of such tests can lead the physician to withhold beneficial human immunoglobulin from a patient who is not actually allergic to this material.

5.2 Thrombosis

SPL UNCLASSIFIED SECTION

Thrombosis may occur following treatment with immune globulin products, including GAMASTAN.(12-14) Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, do not exceed the recommended dose of GAMASTAN. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Boxed Warning, Patient Counseling Information (17)]

5.3 Systemic Reactions

SPL UNCLASSIFIED SECTION

Inject intramuscularly only. Do not administer GAMASTAN intravenously because of the potential for serious reactions (e.g., Renal Dysfunction/Failure/Hemolysis, Transfusion-Related Acute Lung Injury [TRALI]). Do not inject into a blood vessel. [see Dosage and Administration (2.3)]

5.4 Transmissible Infectious Agents

SPL UNCLASSIFIED SECTION

GAMASTAN is made from human blood and may carry a risk of transmitting infectious agents, e. g, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. GAMASTAN is purified from human plasma obtained from healthy donors. When medicinal biological products are administered, infectious diseases due to transmission of pathogens cannot be totally excluded. However, in the case of products prepared from human plasma, the risk of transmission of pathogens is reduced by: (1) epidemiological controls on the donor population and selection of individual donors by a medical interview and screening of individual donations and plasma pools for viral infection markers; (2) testing of plasma for hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), HAV, and human parvovirus (B19V) genomic material; and (3) manufacturing procedures with demonstrated capacity to inactivate/remove pathogens.

No cases of transmission of viral diseases, vCJD, or CJD have ever been identified for products manufactured with the same core manufacturing process as GAMASTAN. ALL infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Grifols Therapeutics LLC [1-800-520-2807].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most common adverse reaction reported for GAMASTAN S/D during post-approval use was fatigue.

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reactions have been identified during post-approval use with GAMASTAN made using the previous manufacturing process, GAMASTAN S/D. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Among patients treated with GAMASTAN S/D, cases of allergic/hypersensitivity reactions including anaphylaxis have been reported. Anaphylactic reactions, although rare, have been reported following the injection of human immune globulin preparations.(11) Anaphylaxis was more likely to occur if GAMASTAN S/D was given intravenously; therefore, GAMASTAN S/D and GAMASTAN must be administered only intramuscularly.

The following have been identified as the most frequently reported post-marketing adverse reactions.

Immune system disorders	Anaphylactic reaction^, hypersensitivity^
Nervous system disorders	Headache
Gastrointestinal disorders	Nausea
General disorders and administration site conditions	Injection site pain, injection site inflammation, fatigue, pyrexia

* These reactions have been manifested by rash, flushing, and dyspnea

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

Antibodies in GAMASTAN may interfere with the response to live virus vaccines such as measles, mumps, polio, rubella, and varicella. Defer live vaccine administration for up to 6 months after GAMASTAN administration.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are no data with GAMASTAN use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with GAMASTAN. It is not known whether GAMASTAN can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation

LACTATION SECTION

Risk Summary

There is no information regarding the presence of GAMASTAN in human milk, the effect on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for GAMASTAN and any potential adverse effects on the breastfed infant from GAMASTAN or from the underlying maternal condition.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in the pediatric population have not been established.

8.5 Geriatric Use

GERIATRIC USE SECTION

Safety and effectiveness in the geriatric population have not been established.

11 DESCRIPTION

DESCRIPTION SECTION

GAMASTAN is a clear or slightly opalescent, and colorless or pale yellow sterile solution of polyvalent human immune globulin for intramuscular administration. GAMASTAN contains no preservative. GAMASTAN is prepared from pools of human plasma collected from healthy donors by a combination of cold ethanol fractionation, caprylate precipitation and filtration, caprylate incubation, anion-exchange chromatography, nanofiltration and low pH incubation. GAMASTAN consists of 15% to18% protein at pH of 4.1 to 4.8 in 0.16 to 0.26 M glycine.

When medicinal biological products are administered, infectious diseases due to transmission of pathogens cannot be totally excluded. However, in the case of products prepared from human plasma, the risk of transmission of pathogens is reduced by epidemiological surveillance of the donor population and selection of individual donors by medical interview; testing of individual donations and plasma pools; and the presence in the manufacturing processes of steps with demonstrated capacity to inactivate/remove pathogens.

In the manufacturing process of GAMASTAN, there are several steps with the capacity for viral inactivation or removal. The main steps of the manufacturing process that contribute to the virus clearance capacity are as follows:

Caprylate precipitation/depth filtration
Caprylate incubation
Depth filtration
Column chromatography
Nanofiltration
Low pH final container incubation

To provide additional assurance of the pathogen safety of the final product, the capacity of the GAMASTAN manufacturing process to remove and/or inactivate viruses has been demonstrated by laboratory spiking studies on a scaled down process model using a wide range of viruses with diverse physicochemical properties.

The combination of all of the above mentioned measures provides the final product with a high margin of safety from the potential risk of transmission of infectious viruses.

The caprylate/chromatography manufacturing process was also investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the variant Creutzfeldt-Jakob disease (vCJD), and Creutzfeldt-Jakob disease (CJD) agents.(15) These studies provide reasonable assurance that low levels of vCJD/CJD agent infectivity, if present in the starting material, would be removed by the caprylate/chromatography manufacturing process.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

The polyclonal antibody in GAMASTAN is a passive immunizing agent to neutralize viruses, such as hepatitis A and measles viruses, to prevent or ameliorate disease.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

The prophylactic value of GAMASTAN is greatest when given before or soon after exposure.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Peak levels of immunoglobulin G are obtained approximately two days after intramuscular injection of GAMASTAN.(16) The half-life of IgG in the circulation of individuals with normal IgG levels is 23 days.(17)

In a clinical study, 12 healthy human subjects received a 20 IU/kg intramuscular dose of HYPERRAB [rabies immune globulin (human)] made using the same manufacturing process as GAMASTAN. Detectable passive rabies neutralizing antibody was present by 24 hours and persisted through the 21 day follow-up evaluation period. The figure below shows the mean levels of rabies virus antibodies in IU/mL across the 21 day evaluation period and indicates that the titer remains stable during this period.

15 REFERENCES

REFERENCES SECTION

Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR-07):1-23.
Centers for Disease Control and Prevention. Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(41);1080-4.
Centers for Disease Control and Prevention. Measles, mumps, and rubella - Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1998;47(RR-08):1-57.
Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60(RR02):1-61.
Centers for Disease Control and Prevention. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(RR04):1-40.
Gershon AA, Piomelli S, Karpatkin M, et al. Antibody to varicella-zoster virus after passive immunization against chickenpox. J Clin Microbiol. 1978;8(6): 733-5.
Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(RR-04):17-8.
Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II. Immunization of adults. MMWR. 2006;55(RR-16):1-33.
Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, et al. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J Med Virol. 1993;40:22-7.
Tejada-Strop A, Costafreda MI, Dimitrova Z, et al. Evaluation of potencies of immune globulin products against hepatitis A. JAMA Intern. Med. 2017;177(3):430-2.
Fudenberg HH. Sensitization to immunoglobulins and hazards of gamma globulin therapy. In: Merler E, editor. Immunoglobulins: biologic aspects and clinical uses. Washington DC: National Academy of Sciences; 1970, p. 211-20.
Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-6.
Woodruff RK, Grigg AP, Firkin FC, et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2:217-8.
Wolberg AS, Kon RH, Monroe DM, et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65,30-4.
Barnette D, Roth NJ, Hotta J, et al. Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process. Biologicals. 2012;40:247-53.
Smith GN, Griffiths B, Mollison D, et al. Uptake of IgG after intramuscular and subcutaneous injection. Lancet. 1972;1(7762): 1208-12.
Waldmann TA, Strober W, Blaese RM. Variations in the metabolism of immunoglobulins measured by turnover rates. In: Merler E, editor. Immunoglobulins: biologic aspects and clinical uses. Washington, DC: National Academy of Sciences; 1970, p. 33-51.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

GAMASTAN is supplied in 2 mL and 10 mL single dose vials. GAMASTAN contains no preservative and is not made with natural rubber latex.

NDC Number	Size
13533-335-04	2 mL vial
13533-335-12	10 mL vial

Store GAMASTAN at 2°C to 8°C (36°F to 46°F).
Do not freeze.
Do not use after expiration date.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient.
Instruct the patient to immediately report symptoms of thrombosis. These symptoms may include: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness or weakness on one side of the body. [see Warnings and Precautions (5.2)]
Inform the patient that GAMASTAN is made from human plasma and may carry a risk of transmitting infectious agents that can cause disease. While the risk that GAMASTAN can transmit an infectious agent has been reduced by screening plasma donors for prior exposure, testing donated plasma, and including manufacturing steps with the capacity to inactivate and/ or remove pathogens, instruct the patient to report any symptoms that concern them. [see Boxed Warning, Warnings and Precautions (5.4)]
Inform the patient that GAMASTAN can interfere with their immune response to live virus vaccines such as measles, mumps and rubella. Inform patients to notify their healthcare professional of this potential interaction when they are receiving vaccinations. [see Drug Interactions (7)]

Manufactured by:

Grifols

Grifols Therapeutics LLC

Research Triangle Park, NC 27709 USA

U.S. License No. 1871

3063873

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LEFT PANEL

NDC 13533-335-12    10 mL

Immune
Globulin
(Human)
GamaSTAN ^®

10 mL

Solution for
Intramuscular Injection

Rx only

FOR INTRAMUSCULAR
INJECTION ONLY.
DO NOT GIVE INTRAVENOUSLY.

GRIFOLS

TOP FLAP

NDC 13533-335-12
GTIN 00313533335120

LOT XXXXXXXXXX
EXP DDMMMYY
SN XXXXXXXXXXXXXXXX

GamaSTAN^®   10 mL

SECOND PANEL

Immune Globulin (Human) is a
sterile solution of immuno-
globulin containing 15%-18%
protein stabilized with 0.16 to
0.26 M glycine.

No U.S. standard of potency for
viral hepatitis antibodies.

10 mL

Not made with natural rubber
latex.

No preservative

Grifols Therapeutics LLC
Research Triangle Park,
NC 27709 USA
U.S. License No. 1871

GRIFOLS

THIRD PANEL

NDC 13533-335-12     10 mL

Immune
Globulin
(Human)
GamaSTAN ^®

10 mL

Solution for
Intramuscular Injection

Rx only

FOR INTRAMUSCULAR
INJECTION ONLY.
DO NOT GIVE INTRAVENOUSLY.

GRIFOLS

Bottom Tab

Carton: 3060459

RIGHT PANEL

The patient and physician
should discuss the risks and
benefits of this product.

One Single-dose Vial

For complete dosage and
administration information,
read enclosed package insert.
Store at 2-8°C (36-46°F).
Do not freeze.

10 mL

Discard unused portion.

If the shrink band is absent or
shows any sign of tampering,
do not use the product and
notify Grifols Therapeutics LLC
immediately.

Not returnable for credit or
exchange.

GRIFOLS

NDC 13533-335-13 10 mL

Immune Globulin (Human)

GamaSTAN ^®

The patient and physician should discuss
the risks and benefits of this product.

One Single-dose Vial

Do not give intravenously.

Dosage: Read package insert.

Grifols Therapeutics LLC
RTP, NC 27709 USA

Rx only
U.S. License No. 1871

3060451

Lot/Exp.

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	SPL version
1809038	GamaSTAN 15-18 % in 10 ML Injection	PSN	36
1809034	GamaSTAN 15-18 % in 2 ML Injection	PSN	36
1809037	immunoglobulin G, human 15-18 % in 10 ML Injection	PSN	36
1809032	immunoglobulin G, human 15-18 % in 2 ML Injection	PSN	36
1809038	10 ML immunoglobulin G, human 180 MG/ML Injection [GamaSTAN]	SBD	36
1809034	2 ML immunoglobulin G, human 180 MG/ML Injection [GamaSTAN]	SBD	36
1809037	10 ML immunoglobulin G, human 180 MG/ML Injection	SCD	36
1809032	2 ML immunoglobulin G, human 180 MG/ML Injection	SCD	36
1809038	10 ML GamaSTAN 180 MG/ML Injection	SY	36
1809034	2 ML GamaSTAN 180 MG/ML Injection	SY	36
1809038	GamaSTAN 15-18 % per 10 ML Injection	SY	36
1809034	GamaSTAN 15-18 % per 2 ML Injection	SY	36
1809037	immunoglobulin G, human 15-18 % per 10 ML Injection	SY	36
1809032	immunoglobulin G, human 15-18 % per 2 ML Injection	SY	36

DailyMed Pharmacologic Classes#

Class, Version, Type table
Class	Version	Type	Effective
HUMAN IMMUNOGLOBULIN G Pharmacologic Class Indexing	2	Indexing - Pharmacologic Class	20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
0ca1d589-929b-4b33-bc5b-1d84abdafa6a	Product name	1	20150324
fc363c46-397b-4476-ac0f-70e43e8e4592	Product name	1	20150324

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
13533-335-04	GamaSTAN	1 in 1 CARTON	INJECTION, SOLUTION	1	36
13533-335-12	GamaSTAN	1 in 1 CARTON	INJECTION, SOLUTION	1	36
13533-335-13	GamaSTAN	10 mL in 1 VIAL	INJECTION, SOLUTION	10	36
13533-335-40	GamaSTAN	2 mL in 1 VIAL	INJECTION, SOLUTION	2	36
13533-635-04	GAMASTAN	1 in 1 CARTON	INJECTION, SOLUTION	1	36
13533-635-12	GAMASTAN	1 in 1 CARTON	INJECTION, SOLUTION	1	36
13533-635-13	GAMASTAN	10 mL in 1 VIAL	INJECTION, SOLUTION	10	36
13533-635-40	GAMASTAN	2 mL in 1 VIAL	INJECTION, SOLUTION	2	36

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
13533-335	GAMASTAN (IMMUNE GLOBULIN (HUMAN)) INJECTION, SOLUTION GAMASTAN (IMMUNE GLOBULIN (HUMAN)) INJECTION, SOLUTION [GRIFOLS USA, LLC]	36	Current NDC, Legacy NDC, 4 package rows	20241004_561f48de-2697-4a35-8233-bd1cdb73438f.zip
13533-635	GAMASTAN (IMMUNE GLOBULIN (HUMAN)) INJECTION, SOLUTION GAMASTAN (IMMUNE GLOBULIN (HUMAN)) INJECTION, SOLUTION [GRIFOLS USA, LLC]	36	Current NDC, Legacy NDC, 4 package rows	20241004_561f48de-2697-4a35-8233-bd1cdb73438f.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
13533-335-04	ML - Milliliter	13533-335	c061f856-c204-460a-acae-446cfeef6303	1	2018-08-13
13533-335-12	ML - Milliliter	13533-335	827c4fa2-d6e3-4816-9ecd-114548734290	1	2018-08-13
13533-335-13	ML - Milliliter	13533-335	0833b051-67e8-49e7-a434-851c6af0a652	1	2018-08-13
13533-335-40	ML - Milliliter	13533-335	a0bf277b-7ff6-4fd0-8b8b-d4ead94aa6d1	1	2018-08-13
13533-635-02	ML - Milliliter	13533-635	c102249c-5e88-45bd-9955-3285dffecfcf	1	2014-10-03
13533-635-04	ML - Milliliter	13533-635	81910d1d-daf2-4fb2-8c3b-e9015576fa05	1	2012-07-24
13533-635-10	ML - Milliliter	13533-635	6d0db6c9-d0d4-47e6-a866-83bd48b57c7a	1	2014-10-03
13533-635-12	ML - Milliliter	13533-635	4a314ce8-c6ee-42ad-a225-eb06e36bba1d	1	2012-07-24
13533-635-13	ML - Milliliter	13533-635	d4305d4b-4268-4253-b2f4-8a1c9918ff82	1	2014-10-03
13533-635-40	ML - Milliliter	13533-635	58035c66-6f1b-4db0-a2cc-a19d09b84174	1	2014-10-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
Human Immunoglobulin G	ACTIVE INGREDIENT	66Y330CJHS	21
Human Immunoglobulin G	ACTIVE MOIETY	66Y330CJHS	21
Glycine	INACTIVE INGREDIENT	TE7660XO1C	21

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

GamaSTAN
immune globulin (human)
Human Immunoglobulin G
Glycine
Water

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
13533-335	13533-335-40, 13533-335-04, 13533-335-13, 13533-335-12
13533-635	13533-635-40, 13533-635-04, 13533-635-13, 13533-635-12

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
101134	Baygam, Gamastan S/D	Immune Globulin (Human)	351(a)	Rx	2026-09-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
Human Immunoglobulin G	66Y330CJHS	ACTIB
Glycine	TE7660XO1C	IACT
Water	059QF0KO0R	IACT
Human Immunoglobulin G	66Y330CJHS	ACTIB
Glycine	TE7660XO1C	IACT
Water	059QF0KO0R	IACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 30 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR	40 mg		Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION / INTRAMUSCULAR		68 mg	Exact identifier — unii+route 30 equally ranked IID candidates
Glycine	GLYCINE	TE7660XO1C	INJECTION, SOLUTION / INTRAVENOUS	0.42 %w/v		Exact identifier — unii+dosage form 30 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
5cda72c1-1ea4-4c71-ab3b-7eddd7d2e445			561f48de-2697-4a35-8233-bd1cdb73438f	2010-10-28	Warnings, Adverse reactions	Exact identifier spl set id: 561f48de-2697-4a35-8233-bd1cdb73438f

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.